The reactivation of latent infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1-5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted-without recurrence in the follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609957 | PMC |
| http://dx.doi.org/10.3390/tropicalmed7100319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Leishmaniasis Masquerading as Diabetic Foot: A Call for Vigilance.
Acta Dermatovenerol Croat
November 2024
Khalid Al Aboud King Faisal Hospital P.O Box 5440, Makkah, Saudi Arabia;
parts of the world (1,2). CL is characterized by significant clinical variability. An ulcerated nodule on the exposed parts of the body (corresponding to the parasite inoculation site by the vector insect) is the classic presentation.
View Article and Find Full Text PDFConcomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation.
Br J Haematol
January 2025
Hematology Laboratory, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
Ritonavir enhances the efficacy of amprenavir: a promising combination therapy by targeting Leishmania DNA Topoisomerase I for treatment of visceral leishmaniasis HIV-VL co-infection.
Exp Parasitol
January 2025
Department of Biotechnology, Savitribai Phule Pune University, Pune-411007, India. Electronic address:
Visceral leishmaniasis (VL) is an opportunistic infection in HIV patients with higher relapse and mortality rate. The number of HIV-VL patients is comparatively higher in areas where both infections are endemic. However, the conventional chemotherapeutic agents have limited success due to drug toxicity, efficacy variance and overall cost of treatment.
View Article and Find Full Text PDFSerosurvey of Visceral Leishmaniasis in Organ Transplant Recipients in the South of Iran.
Transplant Proc
January 2025
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Background: Visceral leishmaniasis (VL) can become active and cause specific problems in transplant recipients. The current study was conducted with the aim of serological evaluation of VL in transplant patients in a comprehensive transplantation center in Fars province southern Iran.
Methods: The study population included 150 organ transplant recipients.
Performance of Culture Using a Semi-Automatic Needle as a Novel Tool for Collecting Lymph Node Samples for the Diagnosis of Canine Visceral Leishmaniasis.
Animals (Basel)
January 2025
Laboratory of Clinical Research on Dermatozoonoses in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Av. Brasil, 4365, Rio de Janeiro 21040-360, Brazil.
Zoonotic visceral leishmaniasis is caused by () and dogs are the main domestic reservoir. This study compared the performance of parasitological tests using semi-automatic needle puncture (SANP) for collecting popliteal lymph node samples with samples collected from the same lymph node by fine needle aspiration puncture (FNAP) and by necropsy for the diagnosis of canine visceral leishmaniasis (CVL). Popliteal lymph node samples were collected from 30 CVL-seropositive dogs from an endemic region in Brazil.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!